<SEC-DOCUMENT>0001178913-25-000026.txt : 20250106
<SEC-HEADER>0001178913-25-000026.hdr.sgml : 20250106
<ACCEPTANCE-DATETIME>20250106085506
ACCESSION NUMBER:		0001178913-25-000026
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250106
FILED AS OF DATE:		20250106
DATE AS OF CHANGE:		20250106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		25509181

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2532512.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.12.1.5274
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div><br>
  </div>
  <div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM 6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of January 2025</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">On January 6, 2025, the Registrant issued the press release which is filed as&#160;Exhibit 1&#160;to this Report on Form 6-K.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">During January 2025, the Registrant sold 5,676,396 of its American Depositary Shares, each representing fifteen (15) ordinary
          shares, par value NIS 0.10 per share, of the Registrant, for total gross proceeds of approximately $1.6 million, through its &#8220;at-the-market&#8221; equity offering program with H.C. Wainwright &amp; Co., LLC, as sales agent.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">This Form 6-K and the press release attached to this Form 6-K as&#160;<a href="exhibit_1.htm">Exhibit 1</a>&#160;are hereby
        incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="za8992f23379a4d6bad1e044a798b14ed" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
          </td>
          <td style="width: 16.16%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 16.16%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 31%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
          </td>
          <td style="width: 16.16%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 31%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Philip A. Serlin</div>
          </td>
          <td style="width: 16.16%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 31%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 16.16%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Dated: January 6, 2025</div>
      <div style="line-height: 1.25;">&#160;<br style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>REGISTRANT'S PRESS RELEASE DATED JANUARY 6, 2025.
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.12.1.5274
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br>
  </div>
  <div style="text-align: right;"><u><font style="font-weight: bold;"> </font></u><br>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Announces $10 Million Registered Direct Offering</div>
    <div style="text-align: left; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">TEL AVIV, Israel, January 6, 2025 -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX)<font style="font-weight: bold;">&#160;</font>(&#8220;BioLineRx&#8221; or the &#8220;Company&#8221;), a development stage biopharmaceutical company
      pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company&#8217;s American Depositary Shares (ADSs) (or ADS equivalents) and
      accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.20 per
      share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date.&#160; Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The closing of the offering is expected to
      occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting the
        placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for research and development activities, the expansion of the Company&#8217;s pipeline of potential drug
        candidates, and working capital and general corporate purposes.</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> The securities described above are being offered pursuant to a &#8220;shelf&#8221; registration statement (File No. 333-276323) filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on December 29, 2023 and
      declared effective on January 5, 2024. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus
      relating to the securities being offered will be filed with the SEC and be available at the SEC&#8217;s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also
      be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>&#160;Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or
      jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</div>
    <div style="text-align: left; line-height: 1.25;">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="text-align: left; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company&#8217;s first approved product is APHEXDA&#174; (motixafortide),
      with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is
      utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.</div>
    <div style="text-align: left; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements (BioLineRx)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Various statements in this release concerning BioLineRx&#8217;s future expectations constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These
      statements include words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; and describe opinions about future events. These include
      statements regarding management&#8217;s expectations, beliefs and intentions regarding, among other things, the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from
      the offering. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results,
      performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx&#8217;s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not
      limited to: the initiation, timing, progress and results of BioLineRx&#8217;s preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx&#8217;s ability to advance its therapeutic candidates into clinical trials or to
      successfully complete its preclinical studies or clinical trials; whether BioLineRx&#8217;s collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of
      real-world results; BioLineRx&#8217;s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx&#8217;s therapeutic
      candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner
      and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx&#8217;s ability to establish, operationalize and maintain corporate collaborations; BioLineRx&#8217;s ability to integrate new therapeutic candidates and new personnel; the
      interpretation of the properties and characteristics of BioLineRx&#8217;s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx&#8217;s business model and
      strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without
      infringing the intellectual property rights of others; estimates of BioLineRx&#8217;s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the&#160;
      commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx&#8217;s industry; and statements as to the impact of the political and
      security situation in Israel on BioLineRx&#8217;s business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the &#8220;Risk Factors&#8221; section of BioLineRx&#8217;s most recent annual report on Form
      20-F filed with the Securities and Exchange Commission on March 26, 2024. In addition, any forward-looking statements represent BioLineRx&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any
      subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="text-align: left; line-height: 1.25;">&#160;</div>
    <div style="text-align: left; line-height: 1.25;">Contacts:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left; line-height: 1.25;">Israel</div>
    <div style="text-align: left; line-height: 1.25;">Moran Meir</div>
    <div style="text-align: left; line-height: 1.25;">LifeSci Advisors, LLC</div>
    <div style="text-align: left; line-height: 1.25;">moran@lifesciadvisors.com</div>
    <div style="text-align: left; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: left; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="line-height: 1.25">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
